1

AstraZeneca 2013 Full Year Results

2

Cautionary statement regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following

cautionary statement: This presentation contains certain forward-looking statements with respect to the operations, performance and financial condition of

the Group. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks

and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted.

The forward-looking statements reflect knowledge and information available at the date of preparation of this presentation and AstraZeneca undertakes no

obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects',

'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-

looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of patents, marketing exclusivity or trade

marks, or the risk of failure to obtain patent protection; the risk of substantial adverse litigation/government investigation claims and insufficient insurance

coverage; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the risk that strategic alliances and

acquisitions will be unsuccessful; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims;

the impact of any failure by third parties to supply materials or services; the risk of failure to manage a crisis; the risk of delay to new product launches; the

difficulties of obtaining and maintaining regulatory approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new

products do not perform as we expect; the risk of environmental liabilities; the risks associated with conducting business in emerging markets; the risk of

reputational damage; the risk of product counterfeiting; the risk of failure to successfully implement planned cost reduction measures through productivity

initiatives and restructuring programmes; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial

prospects; and the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation.

Nothing in this presentation should be construed as a profit forecast.

3

Agenda

Pascal Soriot 2013: Gaining momentum

Marc Dunoyer 2013 financial performance and 2014 guidance

Briggs Morrison Pipeline review

Pascal Soriot Closing remarks

2013: Gaining momentum

Pascal Soriot

Chief Executive Officer, AstraZeneca

5

2013 2014 2015 2016 2017 2018 2019 2020 Beyond 2020

Return to growth Rebuild the

pipeline

Acknowledged leaders in our core TAs

2013 was an important step on our journey

6

Revenue $25,711m -6% (CER)

Core EPS $5.05 -23% (CER)

Dividend per share $2.80

2013 financial results in line with our expectations

7

2013 global revenues in line with our expectations

US 9,691 -9%

Europe 6,658 -9%

Emerging Markets 5,389 +8%

Japan 2,485 +4%

Other established ROW 1,488 -29%

2013

$m

CER

growth

Global Revenue 25,711 -6%

8

Good progress in 2013 across our strategic priorities

Achieve

scientific

leadership

1 Return

to growth

2 Be a great

place to work

3

9

Achieve

scientific

leadership

Late stage pipeline almost doubled and core TAs strengthened

6 additions to late stage pipeline

• Oncology: Olaparib, selumetinib, moxetumomab

• RIA: Benralizumab, PT003

• CVMD: Epanova

Strengthened oncology and other core TAs

• Immunocore, Spirogen, Amplimmune, Fibrogen, Pearl,

Moderna, BMS Diabetes Acquisition

R&D model transformation accelerated

• UK and US changes accelerated, biotech model implemented

Achieve

scientific

leadership

1

Achieve

scientific

leadership

1

10

Good progress in 2013 across our strategic priorities

Achieve

scientific

leadership

Be a great

place to work

Return

to growth

1 2 3

11

Brilinta 283 216

Diabetes 787 75

Respiratory 4,677 7

Emerging Markets 5,389 8

Japan 2,485 4

Growth drivers 12,471 10

2013

$m

CER

growth %

Growth platform revenues up 10% to $12.5bn Return

to growth

2

12

Brilinta: Good progress Europe, International

• 2013 Brilinta revenues up 216%

to $283m

• Leadership position achieved in some

European markets

• Making progress but more work needed in

the US

FY 12

$m

0

50

100

150

200

250

300

FY 13

Note: Growth rates all CER

US $73m

EUR $163m

EST ROW $17m

EM $30m

Return

to growth

2

13

0.8%

1.8%

0.0%

1.0%

2.0%

3.0%

4.0%

5.0%

6.0%

7.0%

8.0%

Aug-11 Oct-11 Dec-11 Feb-12 Apr-12 Jun-12 Aug-12 Oct-12 Dec-12 Feb-13 Apr-13 Jun-13 Aug-13 Oct-13 Dec-13

TRx Share NBRx Share

Return

to growth

2Brilinta: US performance

Source: IMS Health. Copyright 2014. All rights reserved. NPA. Monthly data through December, 2013

OAP Volume

Source: IMS Health. Copyright 2014. All rights reserved. MIDAS; Kantar Health Epi Database; Millennium Research Group; AstraZeneca Global Forecasting Analysis. Note: OAP volume is based on days of therapy. Note: This slide is necessarily forward looking and includes areas for which additional studies may be explored for the purpose of seeking additional indications or expanded labelling

Brilinta: Investing to realise significant potential

• Today: Investments made in Brilinta

promotion, access, affordability,

scientific leadership

• 2014: Commercial focus sharpened across

US, EU and International geographies

• 2016: Significant value creation potential

through LCM programs in post-MI

(PEGASUS), acute stroke (SOCRATES)

& PAD (EUCLID)

% Clinical trial

SOCRATES

EUCLID

PEGASUS

PLATO

Large untapped volume with active

clinical trials to access opportunity

20% ACS

27% Post-ACS

16% Elective Stent

14% PAD

23% Stroke

Return

to growth

2

0

10

20

30

40

50

60

70

80

90

100

20% ACS

27% Post-ACS

16% Elective Stent

14% PAD

23% Stroke

15

Diabetes: building the franchise

• Revenues growing to $787m

• Diabetes acquisition closed 1 February

• Onglyza stable

• Exenatide share growing

• Farxiga US launch 7 February

0

100

200

300

400

500

600

700

800

$m

FY 12 FY 13

Note: Growth rates all CER

Return

to growth

2

Bydureon $151m

Symlin $42m

Onglyza $378m

Forxiga $10m

Byetta $206m

16

17.5%

24.6%

0%

5%

10%

15%

20%

25%

30%

35%

40%

Jul-12 Aug-12 Sep-12 Oct-12 Nov-12 Dec-12 Jan-13 Feb-13 Mar-13 Apr-13 May-13 Jun-13 Jul-13 Aug-13 Sep-13 Oct-13 Nov-13 Dec-13

Bydure

on G

LP

-1 S

hare

TRx Share NBRx Share Exit

Share

Gains

Q1 Q2 Q3 Q4 FY

TRx +2.0 +0.8 +0.8 +0.9 +4.5

NBRx -0.9 -2.1 +1.9 +0.9 -0.2

Return

to growth

2

Source: IMS Health. Copyright 2014. All rights reserved. NPA (December’13 Actuals)

Diabetes: BYDUREON gaining TRx & NBRx share in US

17

Respiratory: Symbicort up 10%

0

500

1,000

1,500

2,000

2,500

3,000

3,500

$m

FY 12 FY 13

Return

to growth

2

• 2013 Symbicort revenues up 10%

to $3,483m

• Symbicort NBRx market share was up

7 points in US

• Share growth in Japan, China and many

International markets

Note: Growth rates all CER

EUR $1,502m +1%

US $1,233m +23%

EST ROW $423m +7%

EM $325m +17%

18

Respiratory: US SYMBICORT Net Sales +23%

Source: IMS Health. Copyright 2014. All rights reserved. NPA (December’13 Actuals)

Return

to growth

2

35.3%

26.2%

18%

20%

22%

24%

26%

28%

30%

32%

34%

36%

Jan-12 Mar-12 May-12 Jul-12 Sep-12 Nov-12 Jan-13 Mar-13 May-13 Jul-13 Sep-13 Nov-13

NBRx TRx Share

2012 Share Growth 2013 Share Growth

+6.81

+3.85

+2.08

+1.53

19

Emerging Markets: Up 8%, driven by China AZ significantly outgrows MNC and total market in China

Growth Rate by Month in China Hospital Market Growth%

YTD Growth Rate 19.5% 14.2% 13.5%

0.0%

5.0%

10.0%

15.0%

20.0%

25.0%

30.0%

35.0%

40.0%

AZ MNC Total China

Source: IMS Health. Copyright 2014. All rights reserved. 13M11data; BISO analysis

Return

to growth

2

Jan-13 Feb-13 Mar-13 Apr-13 May-13 Jun-13 Jul-13 Aug-13 Sep-13 Oct-13 Nov-13

Japan: strong in-market growth

2010 2011 2012 2013

Good performance Growth in brand volume market share

(points)

+4.3 pts

+2.8 pts

+11.5 pts

Dec

Source: IMS Health. Copyright 2014. All rights reserved. Points show 2013 vs. 2012

Return

to growth

2

• AZKK up from 12th to 9th in ranking

• Growth +4% CER

• In-market growth +11%

Source: IMS Health. Copyright 2014. All rights reserved.

21

AstraZeneca 2013 Full Year Results

Marc Dunoyer,

Chief Financial Officer

2013 financial performance and 2014 guidance

23

Headline results 2013

Revenue 6,844 7,282 -4% 25,711 27,973 -6%

Core Operating Profit 1,983 2,795 -26% 8,390 11,159 -22%

Core EPS $1.23 $1.71 -25% $5.05 $6.83 -23%

Q4

2013 FY

2013 FY

2012

Q4

2012 CER CER

24

Core margin FY 2013

Revenue 25,711 -6%

$m

CER

growth

Delta vs

PY CER

%

sales

Core Gross Margin 21,078 -7% 82.0 -50bps

Distribution (306) -3% 1.2 0bps

Core R&D (4,269) +1% 16.6 -110bps

Core SG&A (8,865) +7% 34.5 -430bps

Core Other Income 752 -30% 2.9 -100bps

Core Operating Profit 8,390 -22% 32.6 -690bps

25

Restructuring update

March 2013 Additional activities Feb 2014

COSTS $2.3bn +$0.9bn $3.2bn

CASH $1.7bn +$0.7bn $2.4bn

ANNUAL BENEFITS

ON COMPLETION

(2016)

$0.8bn +$0.3bn $1.1bn

HEADCOUNT

(Gross FTEs) (5,050) (550) (5,600)

26

Net cash from operating activities 7,400 6,948

2013 $m

2012 $m

EBITDA 8,295 10,666

Movement in working capital 166 (706)

Tax & interest paid (1,319) (2,588)

Other non-cash movements 258 (424)

Cash generation: FY 2013

27

Net cash flow after distributions 1,464

2013 $m

Net cash from operating activities 7,400

Net capex (673)

Dividends/share issues (2,979)

Acquisitions and business development (2,273)

Other movements (11)

Cash application: FY 2013

28

Business development aligned with priority TAs

CV/Metabolism Respiratory/Inflammation/ Autoimmune

Oncology Early Stage

Late Stage

NGM

Epanova Hypertriglyceridemia

enteroendocrine cells Diabetes/Obesity mRNA mRNA

AccurinTM nanomedicine

3 preclinical projects

Triple combination LABA/LAMA/ICS

Pearl Triple combination

LABA/LAMA/ICS LABA/LAMA COPD

ACP-501 Reverse cholesterol

transport RDX5791 End stage renal disease

& chronic kidney disease

FG-4592 End stage renal disease &

chronic kidney disease

AMP-514

MK-1775 (WEE1) Antibody-drug

conjugates

Abiraterone acetate Diabetes

29

Cash distributions

• FY 2013 dividend $2.80 per share

• FY 2013: No share repurchases

• FY 2014: No repurchases planned currently

Dividend

Share

repurchases

30

Guidance

Low-to-mid single digit decline 2014 Revenue (CER)

Percentage decline in the teens 2014 Core EPS (CER)

Progressive dividend policy reconfirmed Dividend

Above guidance assumes US Nexium generic end of May 2014

Broadly in line with 2013 2017 Revenue (CER)

31

AstraZeneca 2013 Full Year Results

32

Briggs Morrison, Executive Vice President

Global Medicines Development

Pipeline review

33

Significant phase III & pipeline progression

Exciting assets underpinning scientific leadership

Pipeline review

2013

2014

34

We anticipated 5-7 NME Phase 3 starts 2013-2014

2013 2014

benralizumab

asthma

AZD6765

depression

ATM AVI

serious infections

olaparib

solid tumours

sifalimumab/MEDI-546

systemic lupus erythematosus

AZD4547

gastric cancer

moxetumomab pasudotox

hairy cell leukaemia

mavrilimumab

rheumatoid arthritis

AZD5069

asthma

selumetinib

non-small cell lung cancer

MEDI-551

haematological malignancies

tralokinumab

asthma

Terminated 2015

35

Continuous news flow in 2013 as anticipated Product Milestone

NME

fostamatinib – rheumatoid arthritis Phase III data

naloxegol – opioid-induced constipation Phase III data (KODIAC-08)

moxetumomab pasudotox – hairy cell leukaemia Potential phase III start

olaparib – solid tumours Potential phase III start

CXL – methicillin-resistant Staphylococcus aureus Potential phase III start

benralizumab – asthma Potential phase III start

selumetinib – non-small cell lung cancer Potential phase III start

naloxegol – opioid-induced constipation Submission for approval in USA & Europe

fostamatinib – rheumatoid arthritis Submission for approval in USA & Europe

OTHER

Forxiga – type 2 diabetes (triple therapy) Submission for approval in Europe

Brilinta – acute coronary syndrome Submission for approval in Japan

Forxiga – type 2 diabetes Submission for approval in Japan & China

Zoladex – three month depot (breast cancer) Submission for approval in Japan

Onglyza SAVOR-TIMI53 – outcomes study Study results

brodalumab – psoriatic arthritis Potential phase III start

Forxiga – type 2 diabetes Resubmission for approval in USA

Onglyza SAVOR-TIMI53 – outcomes study Submission for approval in USA &Europe

Bydureon Dual Chamber Pen – type 2 diabetes Submission for approval in USA

FluMist Quadrivalent – flu vaccine Launch in US

Casodex oral dispersible tablet Launch in Japan

2014

36

2013 pipeline delivery

Regulatory

approvals

Farxiga (US)

Xigduo (dapagliflozin+metformin)

(EU)

Fluenz Tetra (EU)

Regulatory

submissions

Epanova (US)

Metreleptin (US)

Olaparib (EU)

Naloxegol (US & EU)

Bydureon dual chamber pen (US & EU)

Phase III

starts

Olaparib in BRCAm Ovarian Cancer

Moxetumomab in hairy cell leukaemia

Benralizumab in severe asthma

Selumetinib in 2nd line KRASm NSCLC

Pipeline

progression

AZD9291 Phase I data

MEDI4736 (PD-L1) Phase I data

MEDI0680 (PD-1) first dose in human

Multiple IMT-C combination trials initiated

Faster than anticipated pipeline progression & re-deployed R&D spend toward late development

Target of 10 potential NMEs in Phase 3

pipeline by 2016 achieved already in 2013

Pipeline progression driving shift

toward late development

9-10

8 6

2016 2013 2012

11

10

8

6

Nu

mb

er

of

NM

Es

in

Ph

as

e 3

pip

eli

ne

Plan Actual

21%

32%

2013 estimate

Late

Development

Early

Development

& Discovery

38%

60%

40%

2013 actual

55%

45%

2014 estimate

50%

50%

38

A growing and accelerating late stage pipeline

Oncology RIA CVMD Neuroscience Infection

CAZ AVI BLI/cephalosporin SBI

Phase 1

33 New Molecular Entities

Small molecule Large molecule

AZD5363 AKT solid tumours

AZD2014

TORK solid tumours

AZD6094 (volitinib) MET solid tumours AZD1208 PIM haems AZD9150 STAT3 haems + solids AZD9291 EGFRm+ solid tumours

AZD8186 PI3Kβδ solid tumours

AZD8848 Inhaled TLR7 agonist asthma AZD7624 Inhaled p38 inhibitor COPD AZD4721 CXCR2 COPD

AZD3293 BSECDR Alzheimer's

MEDI0639 DLL-4 solid tumours MEDI-565 CEA BiTE GI tumours MEDI3617 ANG-2 solid tumours MEDI6469 mOx40 solid tumours

Phase 2

27 New Molecular Entities

Small molecule Large molecule

selumetinib MEK 2L KRAS NSCLC

ATM AVI BL/BLI SBI

AZD4547 FGFR solid tumours

Epanova hypertriglyceridaemia naloxegol opioid induced constipation

Olaparib PARP BRCA ovarian, gastric

metreleptin lipodystrophy

Phase 3

11 New Molecular Entities

Small molecule Large molecule

moxetumomab CD22, HCL brodalumab IL-17R psoriasis benralizumab

IL-5R asthma

AZD1775 Wee-1 ovarian

AZD6423 NMDA suicidal ideation

AZD1419 TLR9 asthma

AZD0914 GHyrAR serious infection

AZD6738 ATR CLL/H&N

PT010 LABA/LAMA/ICS COPD

MEDI0680 PD-1 solid tumours

AZD4901

Hormone modulator PCOS

MEDI4736 PD-L1 solid tumours

MEDI-573 IGF MBC MEDI-551 CD19 CLL, DLBCL tremelimumab CTLA-4 mesothelioma sifalimumab (SLE) IFNa SLE

MEDI-546 IFNaR SLE

MEDI-551 CD19 MS

MEDI5872 B7RP1 SLE MEDI9929 TSLP asthma

MEDI6012 LCAT, ACS MEDI4893 staph alpha toxin SSI MEDI-559 (PRVV) RSV prophylaxis MEDI-550 Panflu library MEDI9287 H7N9 avian influenza

MEDI4736+tremelimumab PD-L1+CTLA-4 solid tumours MEDI4736+dabraf+trametinib PD-L1+BRAF+MEK melanoma

MEDI8968 IL-1R COPD, HS mavrilimumab GM-CSFR RA MEDI7183 α4β7 UC, Crohn’s tralokinumab IL-13 asthma, IPF MEDI2070 IL-23 Crohn’s

RDEA3170 URAT1 - gout

AZD5069 CXCR2 antagonist asthma AZD2115 MABA (dual) COPD

AZD3241 MPO Parkinson's Disease AZD5213 H3R Tourette’s/neuropathic pain

AZD5847 oxazolidinone TB CXL BLI/cephalosporin MRSA

roxadustat (AZD9941) HIF anaemia CKD/ESRD

AZD1722 NHE3 inhibitor ESRD/CKD

lesinurad URAT1 gout PT003 LABA/LAMA COPD

moxetumomab CD22, pALL

olaparib PARP breast selumetinib MEK haems + solids

brodalumab IL-17R asthma/psoriatic arthritis

benralizumab

IL-5R COPD

39

19 candidates for NME registration trial starts in 2014-15

2014 2015

AZD9291

NSCLC

AZD4547

gastric cancer

ATM AVI

serious infections

MEDI4736

solid tumours

MEDI-573

metastatic breast cancer

RDEA 3170

gout

tralokinumab

asthma

MEDI-551

CLL

sifalimumab/MEDI-546

systemic lupus erythematosus

roxadustat (FG4592)

ESRD/CKD

volitinib (AZD6094)

papillary renal cell carcinoma

Pearl Triple PT010

COPD

AZD3293

Alzheimer’s

AZD1775

ovarian cancer

AZD5069

asthma

mavrilimumab

rheumatoid arthritis

MEDI3617

ovarian cancer

AZD1722

ESRD

AZD9150

DLBCL

40

We anticipate 4-5

NME registration

trials

Potential NME registration trial starts in 2014

2014

AZD9291

NSCLC

MEDI4736

solid tumours

tralokinumab

asthma

roxadustat (FG4592)

ESRD/CKD

AZD3293

Alzheimer’s

mavrilimumab

rheumatoid arthritis

MEDI4736 (anti-PD-L1) Empowering the Immune System to Fight Cancer

Novel approach, supporting multiple

combination opportunities

Encouraging level of clinical activity in

Phase I dose-escalation1

• Validated pathway

• Strong scientific rationale for combinations

• Phase I dose-escalation/expansion

monotherapy in solid tumours &

combination trials ongoing, data at ASCO

and ESMO

• Monotherapy phase III start anticipated

in 2014

• PYS potential >$1bn

Ch

an

ge

Fro

m B

as

eli

ne (

%)

100

75

50

25

0

−25

−50

−75

−100

0 50 100 150 200 250

Tumor Assessments (Day)

1 Khleif S, et al. Data presented at an oral session at ECCO/ESMO conference, Amsterdam, Netherlands, 27 Sep - 1 Oct 2013

AZD9291 (3rd generation EGFR-TKI) A novel small molecule targeting key genetic segment in NSCLC

Leading the way in area of high

unmet medical need

Encouraging evidence of

monotherapy activity1

1 Ransom M, et al. Data presented at a mini-oral session at the 15th World Conference of Lung Cancer, Sydney, Australia, 27-30 October 2013

• Oral irreversible inhibitor of both EGFR

sensitising and EGFR T790M resistance

mutations

• Phase I dose-escalation & cohort expansion

in EGFR T790M mutant NSCLC ongoing,

further data at ASCO

• Anticipated to enter Phase III in 2014

• PYS potential >$1bn

Best % change from baseline in target lesions, n=34

% c

ha

ng

e f

rom

ba

seli

ne

in

targ

et

lesio

n

40

20

10

0

–10

–20

–30

–40

–50

–60

–70

–80

–90

–100

30 40

40 40*

40

40 40

40

40 40

40

40

20

20

20

20

20 20 20 20

20 20

20 20

20 20 20

20

20*

D

D D D

D

D§

D§

80

80 80

80

80 80

T790M status

Negative

Positive

Unknown

D Discontinued treatment

* Imputed § Progressive disease due to new lesion

Dose (mg/day) received noted on bar

Population: patients with observed or imputed target lesion data (n=34)

Best overall response#

• 15/35 patients evaluated had a partial response (confirmed + unconfirmed)

• 9/18 patients with T790M+ tumours achieved a partial response (confirmed + unconfirmed)

Preliminary data, cut-off 27 September 2013

#Response Evaluation Criteria in Solid Tumors v1.1, programmatically calculated from investigator-recorded tumour measurements

T790M result from local testing except for some expansion patients where local testing result unknown (central test result used)

Roxadustat/FG4592 Anaemia treatment beyond the boundaries of current ESA therapy

Stimulates EPO production without need

for concomitant iron treatment

First in Class oral HIF-PHD inhibitor

for CKD & ESRD

• Potential first HIF-PHD inhibitor with filing in

2016 (China) and 2018 (US)

• Potential use in Anaemia of Chronic Kidney

Disease (CKD) and End Stage Renal Disease

(ESRD)

• High unmet need for oral agent with

improved safety profile

• Anticipated to enter Phase III in 2014

• PYS Potential >$1bn

AZD3293 (BACE1 inhibitor) Highly potent inhibitor of the first step in Aβ peptide production

Highly promising approach to address

unmet medical need in Alzheimer’s CSF A 42

Day 14 Mean Profiles

AZD3293 (BACE) MAD

Time (hr)

0 3 6 9 12 15 18 21 24

CSF

A42

(% o

f Day

-1 B

asel

ine)

-100

-75

-50

-25

0

25

50

75

Placebo (n=3)

Cohort 1 - 15 mg AZD3293 QD

Cohort 2 - 50 mg AZD3293 QD

CS

F A

4

2 (

% o

f D

ay -

1 B

ase

line

)

Placebo

15mg AZD3293

Time (hours post-dose)

50mg AZD3293

• Alzheimer’s disease pathology is

characterised by A peptide deposition

• Disease causing mutations in APP directly

linked to BACE activity

• Potential to slow disease progression in

prodromal and mild Alzheimer’s disease

• Anticipated registrational trial start in 2014

• PYS potential >$1bn

AZD3293 has demonstrated significant dose

dependent reduction in CSF A in Phase 11

1 Budd H. S. et al (2013) AZD3293 a novel BACE1 inhibitor: Effect on plasma and CSF Abeta peptides following single and multiple-dose administration. Journal of Nutrition, Health and Aging Issue 9, Vol 17

45

Potential NME and LCM submissions 2014-2016

olaparib US

gBRCAm PSR ovarian cancer

PT003

LABA/LAMA COPD

benralizumab

IL-5R asthma

lesinurad

URAT1 gout

brodalumab

IL-17R psoriasis

AZD9291

EGFRm+ solid tumours

CAZ AVI EU

BLI/cephalosporin SBI

metreleptin EU

lipodystrophy

roxadustat (FG4592) CH

HIF anaemia CKD/ESRD

Bydureon Dual Chamber Pen JP

GLP-1 receptor agonist

Brilinta PEGASUS US/EU/JP

ADP receptor antagonist

Brilinta EUCLID US/EU/JP

ADP receptor antagonist

Onglyza SAVOR-TIMI US/EU

DPP-4 inhibitor

Bydureon Autoinjector US/EU

GLP-1 receptor agonist

Brilinta SOCRATES US/EU/JP

ADP receptor antagonist

saxa-dapa FDC US/EU

DPP-4 inhibitor

Iressa IMPRESS EU/JP/CH

EGFRm+ NSCLC

Caprelsa US/EU/JP

differentiated thyroid cancer

Iressa US

EGFRm+ NSCLC

Faslodex US/EU/JP/CH

Oestrogen receptor antagonist

olaparib SOLO-2 US/EU/JP/CH

gBRCAm PSR ovarian cancer

Lesinurad FDC US/EU

URAT1 gout

Oncology

RIA

CVMD

Key:

2016 2015 2014

Infection

46

AstraZeneca 2013 Full Year Results

47

Closing remarks

Pascal Soriot

Chief Executive Officer, AstraZeneca

48

Q3 Q2 Q1 Q4

Carrying momentum into 2014

Epanova, Severe

Hypertriglyceridaemia

PDUFA, May 5

Benralizumab, Tralokinumab

ATS P2 Results Presentations

Analyst Meeting

ATS, May 16 – 21

Medi 4736, Olaparib, AZD 9291

ASCO Results Presentations

Analyst Meeting

ASCO, May 30 – June 3

Saxagliptin/Dapagliflozin,

Type 2 Diabetes

Data In Combined Usage

Bydureon Dual Chamber Pen,

Type 2 Diabetes

Potential FDA Approval

Iressa, NSCLC

Submission US

Olaparib, Ovarian Cancer Platinum

Relapsed

Potential US Approval

CAZ-AVI, Complicated Intra-

Abdominal Infections

P3 Results

Immuno-oncology monotherapy

ESMO Results Presentations

Naloxegol, Opioid Induced

Constipation

PDUFA, September 16

PT-003, COPD

P3 Results

Brodalumab, Psoriasis

P3 Results

Olaparib, Ovarian Cancer Platinum

Relapsed

Potential EU Approval

Dapagliflozin+saxagliptin FDC,

Type 2 Diabetes

FDA Submission

Xigduo XR FDC, Type 2 Diabetes

Potential FDA Approval

Lesinurad, Gout

P3 Results (ACR) and Submission

EU & US

Bydureon Dual Chamber Pen,

Type 2 Diabetes

Potential EU Approval

Farxiga, Type 2 Diabetes

FDA Approval

Dapagliflozin, Type 2 Diabetes

Potential Approval Japan

Olaparib, Ovarian Cancer Platinum

Relapsed

US Submission

Xigduo, Type 2 Diabetes

EU Approval

Naloxegol, Opioid Induced

Constipation

US Ad Comm, postponed

49

Ruud Dobber, EVP, Europe & EVP Global

Portfolio & Product Strategy

(interim)

Bahija Jallal, EVP, MedImmune

Mene Pangalos, EVP, Innovative Medicines

& Early Development

50

AstraZeneca 2013 Full Year Results